CRVSMore money, same molecule
Corvus Pharmaceuticals is topping up its stake in Angel Pharmaceuticals with an additional $5 million as part of a $13.5 million financing round. Translation: the company is still betting that soquelitinib has legs, and it wants more clinical data coming out of China.
Why China matters here
This isn’t just random overseas housekeeping. The financing is meant to support ongoing data generation for soquelitinib in atopic dermatitis and asthma — two programs Corvus is also running in the U.S. If the China work keeps de-risking the asset, that’s the kind of breadcrumb investors like to see before the bigger meal gets served.
The investor angle
For a small biotech, this kind of setup is basically a budget-friendly way to widen the data set without doing everything solo. It can:
- extend the life of the program
- potentially speed up clinical readouts
- give Corvus more shots on goal across two indications
Big picture: Corvus is still very much in “prove it” mode, but this financing says management isn’t tossing soquelitinib into the junk drawer just yet.